FEATURES:
 o
behind the scenes of highly cited research in these interviews
and first-person essays featuring authors of the highly cited
papers in Breast Cancer, as well
as the top-cited scientists in this area. More interviews and
essays are available in the other Special
Topics areas, as well as in in cites
and Science Watch
which are the other editorial components of ISI
Essential
Science Indicators
from ISI.
In addition, the citation statistics for these and other
researchers are available through ISI Essential Science
Indicators data.
|
|
 |
|
|
A profile of:
Dr.
Gary Clark
November
2001
|
|
When
ISI
Essential
Science Indicators
Special Topics analyzed the citations of breast cancer researchers of the 1990s, Dr. Gary Clark, Associate Director of the Breast Center at Baylor College of Medicine, ranked at #6, with 74 papers cited a total of 2,307 times. In the Essential Science Indicators web product, it is shown that Dr. Clark has contributed to 185 papers that have been cited a total of 4,203 times to date in the field of Clinical Medicine.
[read] |
|
An interview with:
Professor Christopher Elston
October
2001
|
|
Professor Christopher Elston of the University of Nottingham discusses
his career in breast cancer research. Prof. Elston, along with his colleague Ian Ellis of the City Hospital of Nottingham, wrote the highly cited paper, "Pathological prognostic factors in breast-cancer 1. The value of histological grade in breast-cancer—Experience from a large study with long-term follow-up,"
(Histopathology 19[5]: 403-10, November 1991). Current data in
ISI
Essential
Science Indicators
Web product indicate that this paper has been cited a total of 621 times.
[read] |
|
|
An interview with:
Dr. Marc
Lippman
October
2001
|
|
Dr. Marc Lippman, formerly of Georgetown University and currently the John Searle Professor and Chair of the Department of Internal Medicine at the University of Michigan Medical School,
discusses his highly cited work in breast cancer research. In the Special Topics Breast Cancer survey, 68 of Dr. Lippman’s papers were cited a total of 2,175 times, ranking him at number seven among the most-cited breast cancer researchers of the past decade.
[read] |
|
|
An interview with:
Dr.
Michael Buckley
September
2001
|
|
Dr.
Michael Buckley, of the Prince of Wales Hospital and the
University of New South Wales in Australia, is the lead author
of the paper, "Expression and amplification of cyclin
genes in human breast-cancer" (Oncogene, 8 [8]: 2127-33,
August 1993), which has been cited a total of 301 times to
date, placing it among the top 20 most-cited papers in breast
cancer research of the 1990’s. In this interview, Dr.
Buckley talks about his work and its impact on the field.
[read] |
|
|
An interview with:
Dr.
Michael Buckley
September
2001
|
|
Dr.
Michael Buckley, of the Prince of Wales Hospital and the
University of New South Wales in Australia, is the lead author
of the paper, "Expression and amplification of cyclin
genes in human breast-cancer" (Oncogene, 8 [8]: 2127-33,
August 1993), which has been cited a total of 301 times to
date, placing it among the top 20 most-cited papers in breast
cancer research of the 1990’s. In this interview, Dr.
Buckley talks about his work and its impact on the field.
[read] |
|
|
An
Interview with:
Dr.
Jorma Isola
September
2001
|
|
Dr. Jorma
Isola, Acting Professor of
Biotechnology and Medical Technology at Tampere University in
Finland, discusses his work with the p53 tumor suppressor gene
in relation to breast cancer prognosis. His paper,
"Association of overexpression of tumor suppressor
protein p53 with rapid cell-proliferation and poor prognosis
in node-negative breast-cancer patients" (Journal of the
National Cancer Institute, 84[14]: 1109-14, 15 July 1992), has
been cited a total of 289 times to date, placing it among the
top 30 most-cited papers in breast cancer research of the 1990’s.
[read] |
|
|
An interview with:
Dr.
Graham Colditz
August
2001
|
|
Dr.
Graham Colditz talks about his research on the relationship
between breast cancer risk and use of postmenopausal hormones.
In our analysis, 75 of Dr. Colditz’s papers were cited a
total of 1,829 times. His most-cited paper is "The use of
estrogens and progestins and the risk of breast-cancer in
postmenopausal women," (New England Journal of
Medicine,
332[24]: 1589-93, 15 June 1995). This paper had been cited 549
times at the time of our analysis, placing it among the top
five most-cited breast cancer papers of the 1990s.
[read] |
|
|
An interview with:
Dr. Khandan Keyomarsi
August
2001
|
|
In this interview, Dr. Khandan Keyomarsi discusses her highly cited paper, "Redundant cyclin overexpression and gene amplification in breast-cancer cells"
(PNAS, 90 [3]: 1112-6, 1 February 1993), and how it has influenced her current research. This paper has been cited 268 times to date, making it one of the top-cited breast cancer research papers of the 1990s.
[read] |
|
|
An interview with:
Dr.
D Craig Allred
July
2001
|
|
Dr.
D. Craig Allred, Professor of Pathology in Breast
Cancer at Baylor College of Medicine in Houston,
Texas, discusses his work with the role of p53 in
breast cancer. His paper, "Association of P53
protein expression with tumor-cell proliferation rate
and clinical outcome in node-negative
breast-cancer," (Journal of the National Cancer
Institute, 85[3]:200-206, 3 February 1993) has been
cited 369 times, making it one of the most highly
cited papers in breast cancer research of the
1990’s.
[read] |
|
|
An interview with:
Dr.
V Craig Jordan
July
2001
|
|
Dr.
V. Craig Jordan of the Northwestern University School of
Medicine is the author of 83 papers, which have been cited a
total of 1,839 times, making him one of the top 20 most-cited
breast cancer researchers of the 1990s. Dr. Jordan was the
first scientist to notice the anticancer properties of
tamoxifen as a preventive, and has had a hand in guiding the
clinical research in this agent. He was recently appointed the
Diana, Princess of Wales, Professor of Cancer Research at
Northwestern. He is also the director of the Lynn Sage Breast
Cancer Research Program, which is affiliated with Northwestern’s
Robert H. Lurie Comprehensive Cancer Center.
[read] |
|
|
|
